TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02440243
Drug: Purethal -placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: preseasonal course of SCIT - three years
Study: NCT00351065
Drug: SK3530
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01518374
Drug: Florbetapir F 18
Normalized name: Florbetapir F 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: 370 MBq (10 mCi)
Study: NCT03688464
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug to be administered for 4 weeks. Subjects will complete surveys prior to initiation and at the end of the study that will assess severity of eczema, quality of life, severity of itch, and sleep quality.
Study: NCT03688464
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug to be administered for 4 weeks. Subjects will complete surveys prior to initiation and at the end of the study that will assess severity of eczema, quality of life, severity of itch, and sleep quality.
Study: NCT02161380
Drug: injection of scAAV2-P1ND4v2 1.18x10e9 vg (Low),
Approvals — FDA: no, EMA: no, PMDA: no
Description: injection of Total Volume of each intravitreal injection is 200 µL
Study: NCT02161380
Drug: injection of scAAV2-P1ND4v2 5.81 X10e9 vg (Med)
Approvals — FDA: no, EMA: no, PMDA: no
Description: injection of Total Volume of each intravitreal injection is 200 µL
Study: NCT02161380
Drug: injection of scAAV2-P1ND4v2 2.4 X10e10vg (High)
Approvals — FDA: no, EMA: no, PMDA: no
Description: injection of Total Volume of each intravitreal injection is 100 µL
Study: NCT02161380
Drug: injection of scAAV2-P1ND4v2 1.0 X10e11vg (Higher)
Approvals — FDA: no, EMA: no, PMDA: no
Description: injection of Total Volume of each intravitreal injection is 100 µL
Study: NCT01870505
Drug: BYL719
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03682692
Drug: ACEI/CCB
Approvals — FDA: no, EMA: no, PMDA: no
Description: benazepril 10 mg / amlodipine besylate 5 mg fixed-dose combination
Study: NCT03682692
Drug: ACEI/DIU
Approvals — FDA: no, EMA: no, PMDA: no
Description: benazepril 10 mg / hydrochlorothiazide 12.5 mg fixed-dose combination
Study: NCT03200340
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match EC-18 capsule administration
Study: NCT02783183
Drug: YHD1119
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 by 2
Study: NCT01013766
Drug: GSK1362885
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg in the AM, 100mg in the PM, 50mg BID
Study: NCT01013766
Drug: GSK1362885
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg in the PM, 100mg in the AM, 50mg BID
Study: NCT02374021
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects entering trial will continue on MTX dose of at least 15mg MTX/week. At the discretion of the treating rheumatologist, may be switched to SQ route.
Study: NCT00207129
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablets, Oral, 1000 mg/m2, Cycle 1: Once (Day 1) Cycle 2: Twice daily (Days 1-5) Cycles 3-18: None, 2 cycles (6 weeks).
Study: NCT03068754
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo for subcutaneous injection
Study: NCT05138913
Drug: TXA
Normalized name: TXA>2<
Approvals — FDA: no, EMA: no, PMDA: no
Description: After the arthroscopic operation was completed, a local TXA injection was performed
Study: NCT01895946
Drug: AZD5363
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral AZD5363 twice daily, 4 days on 3 days off: tablet formulation for one week, followed by two weeks with capsule formulation.
Study: NCT01895946
Drug: AZD5363
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral AZD5363 twice daily, 4 days on 3 days off, tablet formulation. On day 4 AZD5363 tablet without food. On day 11 AZD5363 tablet with food.
Study: NCT02915978
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl delivered via sublingual spray
Study: NCT02915978
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo delivered via sublingual spray
Study: NCT01201187
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1T/twice a day(bid) for 8weeks, po medication
Study: NCT02496910
Drug: YH22162
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02781584
Drug: FIR
Normalized name: Firox
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally once daily
Study: NCT02781584
Drug: VAS
Normalized name: Vasad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally two times daily
Study: NCT02496910
Drug: Chlorthalidone 25mg
Normalized name: CHLORTHALIDONE 25MG TAB
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02205242
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: From day 1 up to and including day 3: 500 mg azithromycin or placebo PO once a day From day 4 up to and including day 90: 250 mg azithromycin or placebo PO once every 2 days
Study: NCT02205242
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01532232
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pts will receive the standard 12-week dosing regimen consisting of 1 mg po of study drug twice daily for 11 weeks,along with smoking cessation counseling, for 11 weeks with an initial dose titration to full strength during the 1st week as follows: 0.5 mg po once daily for 3 days titrated to 0.5mg po twice daily for 4 days. 154 pills will be supplied for the 12 week tx. In order to compensate for any accidentally dropped or lost pills during the study duration, a total of 175 pills will be given to the patient. Along with smoking cessation counseling, for 11 weeks. Pts will receive their medication from the MSK Pharmacy \& equivalent dosing \& side effect education from our Tobacco Cessation Nurse Practitioner. Tx with the study drug will begin after the initial counseling session. Physicians \& tobacco cessation nurses will be blinded regarding pts' assignment to medication or placebo tx arm. Likewise, pts will not be informed as to which medication condition they have been assigned.
Study: NCT03533244
Drug: 0.1% AG-86893 Eye Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop, three times daily to the study eye for 28 days
Study: NCT03533244
Drug: 0.3% AG-86893 Eye Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop, three times daily to the study eye for 28 days
Study: NCT00612196
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00273429
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00242996
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01196416
Drug: Gamma-Secretase Inhibitor RO4929097
Normalized name: .GAMMA.-OCTALACTONE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT02484222
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Before the end of the procedure, spontaneous respiratory was recovered. All the patients were given 1 mcg/kg fentanyl i.v. after the end of the procedure.
Study: NCT00064792
Drug: Simvastatin Susp.
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the simvastatin phase of the trial, therapy will be initiated at 0.5 mg/kg/day for six weeks and then increased to 1.0 mg/kg/day if adverse side effects are minimal or absent.
Study: NCT00064792
Drug: OraPlus
Approvals — FDA: no, EMA: no, PMDA: no
Description: During this trial and for two months prior, patients will be maintained on 150 mg/kg/day of dietary cholesterol (150 mg/ml in OraPlus) for the duration of the trial
Study: NCT01870726
Drug: INC280
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase Ib: INC280 was given at the starting dose of 200mg capsules twice daily with escalation to higher strengths.~Phase II: INC280 was given at the dose of 400mg (tablets) twice daily.
Study: NCT00315016
Drug: eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: active comparator
Study: NCT00315016
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (double dummy)
Study: NCT00682955
Drug: Zinc Sulphate
Normalized name: Zinc sulphate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 mg per day, Zinc Sulphate tablet has been given to subjects.
Study: NCT00682955
Drug: Zinc Sulphate
Normalized name: Zinc sulphate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 mg per day of Zinc Sulphate in suspension form has been given to subjects.
Study: NCT03430232
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short infusion of the solution for intravenous administration, Sodium Chloride 0.9%
Study: NCT03430232
Drug: STR-324 Dose Level B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long infusion of a solution for intravenous administration
Study: NCT03430232
Drug: STR-324 Dose Level C
Normalized name: C.I. acid blue 324
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long infusion of a solution for intravenous administration
Study: NCT03430232
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long infusion of the solution for intravenous administration, Sodium Chloride 0.9%
Study: NCT01248949
Drug: MEDI3617
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive MEDI3617 via IV infusion in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons.
Study: NCT02827136
Drug: hypafix
Normalized name: Dressing Hypafix 2"x10 yd
Approvals — FDA: no, EMA: no, PMDA: no
Description: Appliance of hypafix on both shoulder tip after anesthetic induction
Study: NCT00502008
Drug: Coccinia Cordifolia (herbal extract)
Normalized name: Coccinia grandis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00527904
Drug: PN400 (VIMOVO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects are instructed to take 2 tablets a day, one in the morning and one in the afternoon/evening. The morning tablet should be taken with water, on an empty stomach 30 to 60 minutes before breakfast, or the first meal. The afternoon/evening tablet should be taken with water, on an empty stomach 30 to 60 minutes before dinner. Tablets should be swallowed whole and not broken, crushed or chewed.
Study: NCT00527904
Drug: PN 400 (VIMOVO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg delayed-release naproxen/20 mg immediate release esomperazole dosed twice daily for 12 months
Study: NCT03998969
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablet manufactured to mimic DA-5204
Study: NCT02800083
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02249039
Drug: intermittent IV CLON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanically ventilated infants and children receive intravenous intermittent Clonidine instead of dexmedetomidine
Study: NCT00274677
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental treatment arm
Study: NCT03778450
Drug: Analgesics, Opioid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients are included in the long-term opioid group if they started an opioid-therapy between 2013 and 2017 and received consecutive prescriptions for opioid medications over a minimum of 3 quarters, over a 60-month period between January 1, 2013, and December 31, 2017. The treatment will be assessed using the ATC codes of opioid~treatment N02AA01, N02AA05, N02AB03, N02AE01, N02AX02, N02AX01, N02AX06) reported in reimbursed medicines to patients.
Study: NCT03778450
Drug: Non-Opioid Analgesic
Normalized name: Non-opioid analgesic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with non-opioid pain medication are included, if they received a medication therapy with anticonvulsants (gabapentin, pregabalin, carbamazepine), antidepressants or non-opioid analgesics (NSAIDs, Metamizole) over a minimum of 3 quarters, over a 60-month period between January 1, 2013, and December 31, 2017. The non-opioid treatment will be assessed using the ATC codes (N03AX12, N03AX16, N03AF01) of treatment reported in reimbursed medicines to patients.
Study: NCT02451462
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02384512
Drug: Azilect®
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZILECT® 1mg Tablets
Study: NCT01336153
Drug: MLC601
Approvals — FDA: no, EMA: no, PMDA: no
Description: group A (100 patients; NeuroAid 400mg, 4 capsules 3 times daily) or for 3 month
Study: NCT01336153
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: group B (50 patients; placebo, 4 capsules 3 times daily) for 3 months
Study: NCT00121186
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5 mg/m\^2 on days 1, 3, and 7 post-transplant.
Study: NCT04678388
Drug: Reference drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 Cap., single oral administration under fasting condition
Study: NCT04678388
Drug: Test drug 1
Normalized name: URINE TEST DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 Tab., single oral administration under fasting condition
Study: NCT04678388
Drug: Test drug 2
Normalized name: URINE TEST DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 Tab., single oral administration under fasting condition
Study: NCT01313650
Drug: 62.5/25mcg
Normalized name: TRELEGY ELLIPTA 100/62.5/25MCG INH 14D
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK573719/GW64244
Study: NCT01357252
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02857998
Drug: HMPL-523
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration, once daily
Study: NCT00376454
Drug: GW493838
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04014361
Drug: LY3154885 - Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT04014361
Drug: Placebo - Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT00345618
Drug: Idrabiotaparinux sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mL pre-filled syringe for 3.0 mg~Subcutaneous injection
Study: NCT00345618
Drug: Placebo (for idrabiotaparinux sodium)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mL pre-filled syringe~Subcutaneous injection
Study: NCT00345618
Drug: Placebo (for warfarin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin matching capsules~Oral administration
Study: NCT01737216
Drug: Zoledronic acid plus EP/TP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug:EP/TP+Zoledronic acid EP(VP-16 100mg/m2 d1-3;DDP 60-75mg/m2 d1) every 4 weeks, for 4-6 cycles TP(PTX 135-175mg/m2 d1;DDP 60-75mg/m2 d1) every 3 weeks, for 4-6 cycles Zoledronic acid 4mg d1 every 3 months until bone metastasis, 4mg d1 every 1 month until progression
Study: NCT01737216
Drug: EP/TP
Normalized name: Ethinylestradiol/Testosterone Propionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug:EP/TP EP(VP-16 100mg/m2 d1-3;DDP 60-75mg/m2 d1) every 4 weeks, for 4-6 cycles TP(PTX 135-175mg/m2 d1;DDP 60-75mg/m2 d1) every 3 weeks, for 4-6 cycles
Study: NCT04014361
Drug: LY3154885 - Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT03049735
Drug: Estradiol/norethindrone acetate
Normalized name: Estradiol/Norethindrone Acetate 1 MG-0.5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 (1.0 mg)/NETA (0.5 mg) co-formulated capsule administered orally once daily.
Study: NCT02283645
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03171831
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide（50 mg/kg/day,4 days）
Study: NCT03171831
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate（15mg/m2 on day +1,10mg/m2 on day +3,+6,+11）
Study: NCT01794260
Drug: Cream from Zingiber cassumunar Roxb. extract
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01794260
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00970229
Drug: [123I]MNI-420
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be injected with 8mCi, not to exceed 8.8 mCi (not \> 10% of 8 mCi limit)of \[123I\]MNI-420, followed by SPECT imaging.
Study: NCT01052077
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01052077
Drug: ADT
Normalized name: Radtue
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02790580
Drug: Dose-dense doxorubicin/cyclophosphamide + sunitinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 60mg/m2 day 1, every 2 weeks x 4 cycles Cyclophosphamide 600mg/m2 day1, every 2 weeks x 4 cycles Subcutaneous pegfilgrastim 6mg, 24-36 hours after each cycle of doxorubicin/cyclophosphamide Oral sunitinib 12.5mg daily for 7 days prior to cycle 1 ddAC (days -7 to 0) Oral sunitinib 12.5mg daily for 5 days prior to cycle 2, 3, 4 ddAC (days 10-14 of preceding cycle)~Lumpectomy or mastectomy with sentinel lymph node biopsy or axillary lymph node clearance as appropriate should be considered after completing four cycles of chemotherapy for curative intent in non-metastatic patients and for local control for patients with metastatic disease.
Study: NCT02790580
Drug: Dose-dense doxorubicin/cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 60mg/m2 day 1, every 2 weeks x 4 cycles Cyclophosphamide 600mg/m2 day1, every 2 weeks x 4 cycles Subcutaneous pegfilgrastim 6mg, 24-36 hours after each cycle of doxorubicin/cyclophosphamide~Lumpectomy or mastectomy with sentinel lymph node biopsy or axillary lymph node clearance as appropriate should be considered after completing four cycles of chemotherapy for curative intent in non-metastatic patients and for local control for patients with metastatic disease.
Study: NCT02471391
Drug: ABT-199
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03230526
Drug: [18F]DPA-714 PET scan
Approvals — FDA: no, EMA: no, PMDA: no
Description: One PET scan using \[18F\]DPA-714 is done at M2 between two \[123I\]FP-CIT scan (DaTscan) done at M1 and M23.~Neuropsychological assessment is done at M0, M18 and M24
Study: NCT00217711
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: capecitabine
Study: NCT02823808
Drug: NESINA ACT TAB. 25/15mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin/Pioglitazone 25/15mg will be administered to the group once a day in a fixed dose on a fixed schedule for 104 week.
Study: NCT02823808
Drug: AMARYL-M TAB. 2/500mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glymepiride/Metformin 2/500mg will be administered to the group once a day in a fixed dose on a fixed schedule for 104 week.
Study: NCT00132223
Drug: Contrast agent
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01725594
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03624595
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline) infusion is administered in the same rate for the same duration as in the dexmedetomidine group. The conventional sedation is provided when necessary with propofol and/or midazolam by intravenous infusion/injection. The target depth of sedation depth is RASS -1.
Study: NCT00912457
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 1 p/day for 28 days
Study: NCT00289926
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules of 298.5 mg /capsule Microcrystalline Cellulose, NF 1.5 mg /capsule Magnesium Stearate, NF in a 60 mg Capsule manufactured to mimic the active DHEA capsule
Study: NCT04038853
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo identical to the study intervention drug
Study: NCT00903656
Drug: doxorubicinhydrochloride, Lapatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib 1250mg/d p.o. Caelyx 40 mg/m² i.v. q4w for a maximum of 6 cycles
Study: NCT01474863
Drug: High Dose Citrulline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial intravenous bolus of 20mg/kg (to a maximum of 1500mg) L-citrulline over 10 minutes. Immediately after the initial bolus, a continuous intravenous infusion of L-citrulline at 9mg/kg (max 700mg) per hour will be administered through a dedicated intravenous line or port of a multilumen catheter for 4 days
Study: NCT01474863
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: D5W IV fluids at isovolumetric rate (about 15ml/hr)
Study: NCT01474863
Drug: Low Dose Citrulline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial intravenous bolus of 10mg/kg (to a maximum of 1500mg) L-citrulline over 10 minutes. Immediately after the initial bolus, a continuous intravenous infusion of L-citrulline at 4.5mg/kg (max 350mg) per hour will be administered through a dedicated intravenous line or port of a multilumen catheter for 4 days.
Study: NCT01234194
Drug: rising remifentanil concentrations
Approvals — FDA: no, EMA: no, PMDA: no
Description: remifentanil effect-compartment concentrations 0,1,2,3 ng/ml
Study: NCT01234194
Drug: falling remifentanil concentrations
Approvals — FDA: no, EMA: no, PMDA: no
Description: remifentanil effect-compartment concentrations 3, 2, 1, 0 ng/ml
Study: NCT03286205
Drug: IV iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV iron infusion based on weekly or every 3 week dosage.
Study: NCT03231943
Drug: GSK3640254
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3640254 is a capsule available in 1 milligram (mg), 10 mg and 100 mg dosing strength. GSK3640254 capsule will be given via oral route during each dosing day with approximately 240 mL of water.
Study: NCT03231943
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule matching to the study treatment will be given via oral route during each dosing day with approximately 240 mL of water.
Study: NCT00708175
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone placebo-matching tablets, orally, once daily for up to 52 weeks.
Study: NCT00985322
Drug: non-RAS inhibitor antihypertensive therapy
Normalized name: MAO inhibitors, antihypertensives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood Pressure lowering regimen not including RAS inhibitors
Study: NCT02810899
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline will be administered in the same rate, volume and duration as that in the dexmedetomidine group
Study: NCT02487030
Drug: LDV/SOF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90/400 mg FDC tablet administered orally once daily
Study: NCT01685424
Drug: Etoricoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: As per routine clinical practice in the United Kingdom